

Annual Report
Division of Rheumatology
Department of Medicine - Jewish General Hospital
January 1 - December 31, 2018

Introduction:

A new member of the division is Dr. Valerie Leclair who joined in the spring of 2018. She is currently pursuing a PhD in clinical epidemiology at the Karolinska Institute in Sweden.

Divisional members provide clinical services on Clinical Teaching Unit (CTU), out-patient clinic coverage, consult service as well as supervision of Internal Medicine residents and Rheumatology fellows as follows:

Consult service 3 months/year (Dr. Baron, Dr. Berkson, Dr. Fallavollita, Dr. Gyger); Dr. Hudson Dr.

Leclair: 1 month

Out-patient clinic (Dr. Baron 7 ½ days per week; Dr. Berkson 6 ½ days per week; Dr. Fallavollita 6 ½ days per week; Dr. Gyger 7 ½ days per week)

Musculoskeletal ultrasound (Dr. Fallavollita 1 day)

Video capillaroscopy (Dr. Gyger ½ day)

In-Patient Follow up (Dr. Hudson 3 hours/day)

Supervision of research trainees for 2 half-days per week (Dr. Hudson 8 hours)

Staff members strive for clinical innovation. Dr. Baron has an ongoing scleroderma clinical, rheumatic disease/lung clinic.

1. Research and publications:

Dr. Baron's primary research interest is scleroderma. Dr. Baron has established the Canadian Scleroderma Research Group (CSRG) and the International Systemic Sclerosis Inception Cohort. Dr. Baron's research has focused on ways of measuring disease activity and damage in scleroderma. In April 2018 he organized and held the first meeting of Canadian rheumatologists and hematologists interested in advancing the use of autologous hematopoietic stem cell transplants for scleroderma in Canada. He is involved multiple working groups of the Scleroderma Clinical trials Consortium and site on the extended executive

Dr. Hudson was on sabbatical leave during the 2018-2019 academic year to develop a program of research in cellular therapies for systemic autoimmune rheumatic diseases. She has also recently been named Co-director (Immunity) of MI4. She has also been asked to sit as a member of the McGill University Department of Medicine Departmental Promotions/Tenure Committee.

Dr. Leclair is enrolled as a PhD student in Clinical Epidemiology at Karolinska Institutet in Stockholm Sweden under the supervision of Dr. Marie Holmqvist in the myositis research group of Prof Ingrid Lundberg. Her research projects are focused on different clinical phenotypes in myositis and their impact on clinical outcomes.

2. Teaching and learning (undergraduate and graduate):

The division continues to participate in undergraduate and post-graduate medical education. Its members provide clinical supervision to medical students, residents and fellows regularly during their

2-week as attendings on the medical wards, full-day weekly general rheumatology clinics and consult service. They participate in the CaRMS Admission Committee for Internal Medicine (3 hours/year).

Dr. Berkson continues as Osler fellow in 2018, and as Chair of the Program Evaluation and Curricular Outcomes Committee UGME. In 2018 she delivered JGH Grand Rounds on Giant Cell Arteritis, as well as an audiovisual recording on GCA for the Internal Medicine residents.

Dr. M. Baron

2 weeks on medical ward
3 months on rheumatology consult service,
Frequently with students and residents in outpatient clinic
Co-supervision of rheumatology fellow with Dr. Hudson

Dr. L. Berkson

Osler Fellow 4 hours/ month
12 weeks attending on consult service
½ day per week supervising residents in ambulatory care

Dr. S. Fallavollita

Working on developing US curriculum for students
Teaching undergraduate / postgraduate students and fellows
Chair of TCP at McGill

Dr. G. Gyger

Capillaroscopy course at the Rheumatology week-end (12 hours)
Capillaroscopy course to rheumatologists (around 25-30 hours per doctor)
RAC course (13 hours 45 min)
Scleroderma introduction yearly (1 hour)
Scleroderma GI disease and capillaroscopy for pediatric fellows (45 min)
6 hrs "MSK Physical exam" 1st year medicine small group on introduction to MSK exam

Post Graduate Teaching

15 hrs McGill Simulation Center: Ethics (Internal Medicine R2 and 3)
Shoulder and Knee Injection and Aspiration (Internal Medicine R4)
3 hrs McGill Internal Medicine PGY4 Academic Half Day MSK exam
1 hr Family Medicine academic half day: Commonly encountered joint complaints
1 hr Internal Medicine PGY4 half day: Approach to Rheumatoid Arthritis
1 hr Academic half-Day: Rheumatology
1 hr Rheumatology Fellows: Approach to joint injections
72 hrs Internal Medicine TCP small group Teaching
10 hrs what is rheumatoid Arthritis
3 hrs/ week 2 residents
Supervision of Fellow Continuity Clinic
JGH Site Director Rheumatology Program
Supervision of trainees (undergraduate and postgraduate)

3. Involvement in the community:

Dr. Baron holds the position of immediate past President of the Scleroderma Clinical Trials Consortium.

Dr. Hudson co-leads a Scleroderma Clinical Trials Consortium working group on scleroderma renal crisis.

Dr. Hudson is medical advisor for Myositis Canada, a national grass-roots advocacy organization and AWISH, a local self-help group for patients with arthritis.

We have initiated our own vaccine clinic for our patients who are immunocompromised.

4. Partnerships:

Dr. Berkson is collaborating with Dr. Vartan Mardigyan (cardiology) in the treatment of patients with refractory pericarditis.

Dr. Fallavollita is a member of a national organization developing a core clinical dataset for quality care for Rheumatoid Arthritis

Dr. Gyger is part of an international consortium studying rare GI manifestations of scleroderma.

Dr. Gyger is on a committee of the Scleroderma Clinical Trials Consortium seeking to establish training programs and a certification process for the use of video capillaroscopy in Scleroderma

The rheumatology research group has instituted the development of a new international research organization called The International Systemic Sclerosis Inception Cohort (InSync) with the aim of closely following the first few years of illness in patients with scleroderma from many different countries to develop a large enough cohort for important research. In Sync includes researchers from Canada, United States, Germany, Holland, Sweden, Australia and Spain.

Dr. Baron is past President of scleroderma clinical trials consortium, a worldwide body of scleroderma researchers.

Dr. Hudson participates in numerous local, national and international research networks including CSRG, INSYNC, Tri-Nation cohort, SCTC, CIMS, MIRAE, and CAN-RiO.

The Division runs an osteoporosis clinic in partnership with endocrinology. It has a once/month clinic for rheumatic disease with lung disease and/or pulmonary hypertension. Scleroderma patients are seen once per week for collection of data for the Canadian Scleroderma Research group.

5. Milestones: There were no changes in staffing except as above.

6. Honours, awards, and prizes:

Dr. Sabrina Hoa, a post-doctoral fellow under the supervision of Dr. Hudson, was awarded The Arthritis Society's Post-doctoral fellowship award (2016-18), the CIHR Canada Graduate Scholarship award (2017-2019), the Fonds de recherche du Québec- Santé master award (2017-2019), the Drug Safety and Effectiveness Cross-Disciplinary Training (DSECT) Program award (2017-2018), and the Fondation du Centre Hospitalier de l'Université de Montreal Scleroderma Research Chair award (2017-2018). She was appointed as Assistant professor at the Centre Hospitalier de l'Université de Montreal in January 2019.

Under the supervision of Dr. Hudson, Sophie Wojcik (PGY4, Rheumatology) won Best Abstract by a Rheumatology Fellow, Jessica Salituri (PGY2 Internal Medicine) won Best Abstract on Basic Science Research by a Trainee, and Tedi Qendro (Second year medical student, McGill University) won Best Abstract by a Medical Student at the Canadian Rheumatology Association meeting held in February 2018 in Vancouver, BC

Dr. Leclair received funding for her PhD salary from the Dahlin Börje foundation in Stockholm, Sweden.

7. Fundraising: None to report

SECTION I - DIVISION STATUS UPDATE

1. Mission and objectives of the Division

The Division strives to provide high level clinical care, education and research.

2. A nominative list of academic staff, their academic rank

Murray Baron, MD: Professor of Medicine
Marie Hudson, MD: Associate Professor with tenure
Genevieve Gyger, MD: Assistant Professor
Laeora Berkson, MD: Associate Professor of Medicine
Sabrina Fallavollita, MD: Assistant Professor
Valerie Leclair, MD: Assistant Professor

SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF McGill

1. Grants and awards received

Baron, Murray

Scleroderma Society of Ontario
-Canadian Scleroderma Research Group

Grouping of Canadian Companies and Corporations:

-A multicenter, open label study to describe the safety of daily subcutaneous injections of Anakinar (r-metHuIL-1ra) in patients with rheumatoid arthritis.

University of Michigan

-A phase II study to evaluate subcutaneous abatacept vs placebo in diffuse cutaneous systemic sclerosis- a double-blind, placebo-controlled, randomized controlled trial (IM101-344)(ASSET)

Bayer (Canada) Inc

-A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat in patients with diffuse cutaneous systemic sclerosis (dcSSc) (Study 16277)

Mount Sinai Hospital:

-The Canadian ArTHritisCoHort (CATCH): A prospective cohort study of adults with new-onset inflammatory arthritis symptoms.

Hoffmann-La Roche Ltd, Canada :

-A Phase II/III, multi-centre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of tocilizumab versus placebo in patients with systemic sclerosis.

JSS Medical Research

-A Canadian randomized controlled trial (RCT) of real world Cimzia treatment in RA: Randomizing to stop vs continued DMARDs.

Abbott Laboratories:

-Real life evaluation of rheumatoid arthritis in Canadians taking HUMIRA.

Hudson, Marie

-Personal Support Awards

Fonds de la recherche en santé du Québec (FRSQ)

Recherches observationnelles portant sur les maladies systemiques autoimmunes rhumatismales
2015-2019, Chercheur-clinicien Senior

2018/11-2019/11 World Scleroderma Foundation

Development and evaluation of a patient decision aid for autologous hematopoietic stem cell transplantation in systemic sclerosis

Co-Investigator with Thombs, Brett; Thonen-Velthuisen, Jessicas; Schraven, Linda

PI: Kwakkenbos L

\$50,000

2018/08-2021/07 Genome Canada/Genome Quebec

Precision Medicine in Cellular Epigenomics

Co-Investigator with Lakhali-Chaieb, Lajmi; Daley, Denise; Labbe, Aurélie; Zhang, Tieyuan

PIs: Greenwood, Celia and Oualkacha, Karim

\$660,512

2018/03-2019/02 Canadian Institutes of Health Research, Patient-Oriented Research Collaboration Grants.

Developing a Program to Enhance Physical Activity in Scleroderma: The SPIN-PACE Study

Co-Investigator with Bartlett, Susan; Fortune, Catherine; Godard, Dominique; Gottesman, Karen;

Guillot, Genevieve; Kwakkenbos, Linda; Carrier, Marie-Eve; Leite, Catarina; Mouthon, Luc; Nielsen, Karen; Portales Guiraud, Alexandra

PIs: Shrier I, Thombs BD, Sauve M, Pelaez S

\$40,000

2018/02-2019/01 CIHR

The Scleroderma Support group Leader Education (SSLED) Program

Co-applicant; Principal Investigator Dr. Brett Thombs

\$100,000

2018/07-2019/06 BMS
MIRAE
PI \$35,000

2018/12-2019/11 Roche
MIRAE
PI \$35,000

Current (ordered by end date)

06/2017 - 01/2020
Bringing Patients and Therapies Together Sooner: Building Clinical Research Capacity to Improve Outcomes in Myositis
CIORA PI \$119,300

10/2016 - 09/2019
Randomized Controlled Trial of an Internet-based Exercise Program to Improve Hand Function in Patients with Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Study (Thombs)
TAS Co-PI \$359,686

07/2016 - 07/2019
Randomized Controlled Trial of an Internet-based Scleroderma Self-Management Program: A Scleroderma Patient-Centered Intervention Network (SPIN) Study (Thombs)
CIHR Co-PI \$561,909

08/2016 - 07/2019
Pragmatic, multicentre, cluster, cohort randomised controlled treat-to-target trial for treatment of small intestinal bacterial overgrowth in SSc (Baron)
CIHR Co-PI \$117,000

08/2017 - 02/2018
Scleroderma Renal Crisis Working group
SCTC PI \$12,000 US

05/2017 - 05/2018
Proteomic analysis of Inflammatory Myopathies – A Pilot Project
MyoCan PI \$10,000

06/2015 - 01/2018
Preventing rheumatoid arthritis (Pre-RA) PI
\$82,933 - 02/2017

01/2018
NT-proBNP to screen for SSc-PAH
Roche PI \$50,000

Fallavollita, Sabrina

JSS Medical Research:

-Prospective observational study to evaluate the use of musculoskeletal ultrasonography to improve rheumatoid arthritis management: Canadian experience (Echo Study).

MUHC PI: Dr. Ines Colmegna:

-liT Profile and functional implications of the production of age- associated inflammatory cytokines by hematopoietic progenitor cells in RA

Abbott Laboratories Ltd:

-Drug Canadian HUMIRA. Post Marketing Observational Epidemiological Study: Assessing Effectiveness in AS. Site contact and in charge of patient recruitment

2. Research Trainees Supervised

Hudson, Marie

Dr. Hudson supervised 16 research trainees during 2018, of which her PDF won multiple training awards and 3 trainees won awards for posters/presentations at the Canadian Rheumatology Association meeting in Vancouver (February 2018).

2. Scholarly works published in the 2018 calendar year

1. Ross L, Prior D, Proudman S, Vacca A, **Baron M**, Nikpour M. Defining primary systemic sclerosis heart involvement: A scoping literature review. *Seminars in arthritis and rheumatism* 2018.
2. Richard N, **Hudson M**, Wang M, **Gyger G**, Proudman S, Stevens W, Nikpour M, **Baron M**. Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. *Rheumatology (Oxford, England)* 2018.
3. Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirjak L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, **Hudson M**, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt O, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Muller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanc M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. *Rheumatology (Oxford, England)* 2018;57:370-81.
4. Peschken CA, Wang Y, Abrahamowicz M, Pope J, Silverman E, Sayani A, Iczkovitz S, Ross J, Zummer M, Tucker L, Pineau C, Levy D, **Hudson M**, Hitchon CA, Huber AM, Smith CD, Avina-Zubieta A, Arbillaga H, Chedeville G, Wynant W, Fortin PR. Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. *The Journal of rheumatology* 2018.
5. Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, **Hudson M**, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL. Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. *Journal of scleroderma and related disorders* 2018;3:249-52.
6. Munro S, Spooner L, Milbers K, **Hudson M**, Koehn C, Harrison M. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. *BMC rheumatology* 2018;2:18.

7. Morrisroe K, **Hudson M**, **Baron M**, de Vries-Bouwstra J, Carreira PE, Wuttge DM, Wang M, Frech TM, Stevens W, Proudman SM, Nikpour M. Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. *Clinical and experimental rheumatology* 2018;36 Suppl 113:53-60.
8. Montastruc F, Renoux C, Dell'Aniello S, Simon TA, Azoulay L, **Hudson M**, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study. *Rheumatology (Oxford, England)* 2018.
9. Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Chiovitti MJ, Sanchez TA, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, **Baron M**, Beraldi A, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Chowdhary N, Clover K, Conwell Y, de Man-van Ginkel JM, Delgadillo J, Fann JR, Fischer FH, Fischler B, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Hambridge J, Harrison PA, Hegerl U, Hides L, Hobfoll SE, **Hudson M**, Hyphantis T, Inagaki M, Ismail K, Jette N, Khamseh ME, Kiely KM, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Lowe B, Marsh L, McGuire A, Mohd Sidik S, Munhoz TN, Muramatsu K, Osorio FL, Patel V, Pence BW, Persoons P, Picardi A, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van der Feltz-Cornelis CM, van Weert HC, Vohringer PA, White J, Whooley MA, Winkley K, Yamada M, Zhang Y, Thombs BD. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. *The British journal of psychiatry : the journal of mental science* 2018;212:377-85.
10. Landon-Cardinal O, Prince F, Bedard S, Benveniste O, **Hudson M**. Dermoskeletons to preserve mobility and function in inclusion body myositis. *Neurology* 2018;91:760.
11. Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier ME, **Hudson M**, van den Ende CHM, Schouffoer AA, Welling J, Sauve M, Thombs BD, and the SI. The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. *Clinical and experimental rheumatology* 2018;36 Suppl 113:88-94.
12. Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier ME, **Hudson M**, van den Ende CHM, Schouffoer AA, Welling J, Sauve M, Thombs BD. The association of sociodemographic and disease variables with hand function: a Scleroderma Patient-centered Intervention Network cohort study. *Clinical and experimental rheumatology* 2018;36 Suppl 113:88-94.
13. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, **Baron M**, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Muller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSSciate). *Annals of the rheumatic diseases* 2018;77:212-20.
14. Johnson SR, Soowamber ML, Fransen J, Khanna D, Van Den Hoogen F, **Baron M**, Matucci-Cerinic M, Denton CP, Medsger TA, Jr., Carreira PE, Riemekasten G, Distler J, Gabrielli A, Steen V, Chung L, Silver R, Varga J, Muller-Ladner U, Vonk MC, Walker UA, Wollheim FA, Herrick A, Furst DE, Czirjak L, Kowal-Bielecka O, Del Galdo F, Cutolo M, Hunzelmann N, Murray CD, Foeldvari I, Mouthon L, Damjanov N, Kahaleh B, Frech T, Assassi S, Saketkoo LA, Pope JE. There is a need for new systemic sclerosis subset criteria. A content analytic approach. *Scandinavian journal of rheumatology* 2018;47:62-70.
15. Ishihara M, Harel D, Levis B, Levis AW, Riehm KE, Saadat N, Azar M, Rice DB, Sanchez TA, Chiovitti MJ, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Arroll B, Bombardier CH, Butterworth P, Carter G, Clover K, Conwell Y, Goodyear-Smith F, Greeno CG, Hambridge J, Harrison PA, **Hudson M**, Jette N, Kiely KM, McGuire A, Pence BW, Rooney AG, Sidebottom A, Simning A, Turner A, White J, Whooley MA, Winkley K, Benedetti A, Thombs BD. Shortening self-report mental health symptom measures through optimal test assembly

- methods: Development and validation of the Patient Health Questionnaire-Depression-4. Depression and anxiety 2018.
16. Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirjak L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuta C, Ong VH, Farge D, **Hudson M**, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt O, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Muller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanc M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. *Annals of the rheumatic diseases* 2018;77:563-70.
 17. Harel D, **Baron M**. Methods for shortening patient-reported outcome measures. *Statistical methods in medical research* 2018;962280218795187.
 18. Gumuchian ST, Pelaez S, Delisle VC, Carrier ME, Jewett LR, El-Baalbaki G, Fortune C, **Hudson M**, Korner A, Kwakkenbos L, Bartlett SJ, Thombs BD. Understanding coping strategies among people living with scleroderma: a focus group study. *Disability and rehabilitation* 2018;40:3012-21.
 19. Fritzler MJ, **Hudson M**, Choi MY, Mahler M, Wang M, Bentow C, Milo J, **Baron M**, Canadian Scleroderma Research G. Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. *Autoimmunity reviews* 2018;17:267-75.
 20. Fritzler MJ, **Hudson M**, Choi MY, Mahler M, Wang M, Bentow C, Milo J, **Baron M**. Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. *Autoimmunity reviews* 2018;17:267-75.
 21. Douros A, Abrahami D, Yin H, Yu OHY, Renoux C, **Hudson M**, Azoulay L. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes. *Epidemiology (Cambridge, Mass)* 2018;29:904-12.
 22. Dougherty DH, Kwakkenbos L, Carrier ME, Salazar G, Assassi S, **Baron M**, Bartlett SJ, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mouthon L, Nielson WR, Poiraudau S, Sauve M, Boire G, Bruns A, Chung L, Denton C, Dunne JV, Fortin P, Frech T, Gill A, Gordon J, Herrick AL, Hinchcliff M, **Hudson M**, Johnson SR, Jones N, Kafaja S, Larche M, Manning J, Pope J, Spiera R, Steen V, Sutton E, Thorne C, Wilcox P, Thombs BD, Mayes MD, Investigators S. The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. *Rheumatology (Oxford, England)* 2018;57:1623-31.
 23. de Boer SM, Powell ME, Mileshekin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, **Baron MH**, Jurgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens L, Smit V, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. *The Lancet Oncology* 2018;19:295-309.
 24. Caron M, Hoa S, **Hudson M**, Schwartzman K, Steele R. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. *European respiratory review : an official journal of the European Respiratory Society* 2018;27.
 25. Barbacki A, Maliha PG, **Hudson M**, Small D. A case of severe Pembrolizumab-induced neutropenia. *Anti-cancer drugs* 2018;29:817-9.
 26. Barbacki A, Fallavollita SA, Karamchandani J, **Hudson M**. Immune-Mediated Necrotizing Myopathy and Dietary Sources of Statins. *Annals of internal medicine* 2018;168:893-904.

27. Azar M, Rice DB, Kwakkenbos L, Carrier ME, Shrier I, Bartlett SJ, **Hudson M**, Mouthon L, Poiraudreau S, van den Ende CHM, Johnson SR, Rodriguez Reyna TS, Schouffoer AA, Welling J, Thombs BD, investigators S. Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *Disability and rehabilitation* 2018;40:1997-2003.
28. Azar M, Rice DB, Kwakkenbos L, Carrier ME, Shrier I, Bartlett SJ, **Hudson M**, Mouthon L, Poiraudreau S, van den Ende CHM, Johnson SR, Rodriguez Reyna TS, Schouffoer AA, Welling J, Thombs BD. Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. *Disability and rehabilitation* 2018;40:1997-2003.
29. Arnold MB, Khanna D, Denton CP, van Laar JM, Frech TM, Anderson ME, **Baron M**, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Riemekasten G, Steen V, Muller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE, Pope JE. Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. *Rheumatology (Oxford, England)* 2018;57:152-7.
30. **Leclair V**, Labirua A, Lundberg IE. Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with anti-melanoma differentiation-associated gene 5 antibodies. *J Rheumatol* 2018;45(4):581-583.
31. **Leclair V**, Lundberg IE. New Myositis Classification Criteria—What We Have Learned Since Bohan and Peter. *Curr Rheumatol Rep* 2018;20(4):18.

2018 Published abstracts

1. Bangert E, **Hudson M**, Vinet E, Wang M, **Gyger G**. Nailfold videocapillaroscopy in idiopathic inflammatory myopathies. *Journal of Rheumatology* 2018;45 (7):1024.
2. Bansback N, **Hudson M**, Koehn C, Laba TL, Harrison M. How to design clinical trials to be more patient oriented: an example from preventative treatments for rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2018;77 (Supplement 2):827.
3. Butler EA, Wang M, Denton C, **Hudson M**. An international delphi exercise to identify a core set of items to develop classification criteria for scleroderma renal crisis. *Journal of Rheumatology* 2018;45 (7):1026.
4. Caron M, Schwartzman KJ, **Hudson M**, **Baron M**, Steele RJ. Capturing systemic sclerosis-associated interstitial lung disease onset: A comparison of common definitions and an advanced statistical model. *American Journal of Respiratory and Critical Care Medicine Conference: American Thoracic Society International Conference, ATS* 2018;197.
5. Da Costa D, Neville C, Julien AS, Rochon M, Eng D, Peschken CA, Vinet E, Smith CD, Matsos M, Pope JE, Clarke AE, Keeling S, Avina-Zubieta JA, **Hudson M**, Fortin PR. A pan-canadian study of factors associated with perceived doctor-patient communication in patients with systemic lupus erythematosus. *Arthritis and Rheumatology* 2018;70 (Supplement 9):2589.
6. Fisher A, Dormuth C, **Hudson M**. Persistence on tofacitinib therapy in rheumatoid arthritis. *Pharmacoepidemiology and Drug Safety* 2018;27 (Supplement 2):471.
7. Fortin PR, Neville C, Julien AS, Rochon M, Eng D, Peschken CA, Vinet E, **Hudson M**, Smith D, Matsos M, Pope JE, Clarke AE, Keeling S, Avina-Zubieta JA, Da Costa D. Activation towards health self-management in patients with systemic lupus erythematosus. *Arthritis and Rheumatology* 2018;70 (Supplement 9):3010-1.
8. Harrison M, Bansback N, Spooner L, Koehn C, **Hudson M**. Preventing rheumatoid arthritis (pre-RA): Preferences of potential recipients, patients, and health care professionals for preventative treatment. *Journal of Rheumatology* 2018;45 (7):967.

9. Hudson J, Lewis K, Senecal J, Kiepas A, Tabaries S, Sabourin V, Ahn R, Selva RL, Siegel P, Ursini-Siegel G. P66ShcA is a contextual breast cancer metastasis promoter or suppressor depending on the tumor microenvironment. *Cancer Research Conference* 2018;78.
10. Kwakkenbos L, Carrier ME, Boutron I, Welling J, Sauve M, Van Den Ende C, Schouffoer AA, **Hudson M**, Thombs BD, Mouthon L. Randomized feasibility trial of the scleroderma patient-centered intervention network hand exercise program (SPIN-HAND). *Journal of Scleroderma and Related Disorders* 2018;3 (Supplement 1):204.
11. Kwakkenbos L, Dougherty DH, Carrier ME, Salazar G, Assassi S, **Baron M**, Bartlett SJ, Furst DE, Gottesman K, Van Den Hoogen F, Malcarne VL, Mouthon L, Nielson W, Sauve M, Thombs BD, Mayes MD. The scleroderma patient-centered intervention network (SPIN) cohort: Baseline clinical features and comparison to other large scleroderma cohorts. *Journal of Scleroderma and Related Disorders* 2018;3 (Supplement 1):246.
12. Kwakkenbos L, Sanchez TA, Turner KA, Mouthon L, Carrier ME, **Hudson M**, Van Den Ende CHM, Schouffoer AA, Welling JJKC, Sauve M, Thombs BD. The association of sociodemographic and disease variables with hand function: A Scleroderma Patient-centered Intervention Network cohort study. *Clinical and Experimental Rheumatology* 2018;36:S88-S94.
13. Lora M, Shimabukuro N, Cheng A, **Hudson M**, Colmegna I. Methotrexate enhances the immunopotency of human mesenchymal stromal cells. *Journal of Rheumatology* 2018;45 (7):1055.
14. Mahler M, Bentow C, Milo J, **Hudson M**, **Baron M**, Choi M, Fritzler MJ. Identification of an immunodominant epitope on RNPC-3 as a target of autoantibodies in patients with systemic sclerosis. *Arthritis and Rheumatology* 2018;70 (Supplement 9):880-1.
15. Maliha P, **Hudson M**, Abikzher G, Probst S. Screening for cancer in autoimmune myopathies with FDG-PET/CT. *European Journal of Nuclear Medicine and Molecular Imaging* 2018;45 (Supplement 1):S317.
16. Maltez N, **Hudson M**, Troyanov Y, Choi M, Wang M, Fritzler M, **Baron M**, Smith D. Trigeminal neuralgia in systemic sclerosis. *Journal of Rheumatology* 2018;45 (7):1012.
17. Meti N, Esfahani K, Colmegna I, Fritzler MJ, Johnson NA, Piccirillo C, Miller WH, **Hudson M**. Elevated SCD40L as a predictive biomarker of immune-related adverse events in patients receiving immune checkpoint inhibitors. *Arthritis and Rheumatology* 2018;70 (Supplement 9):387-8.
18. Munro S, Spooner L, Milbers K, **Hudson M**, Koehn C, Harrison M. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: A qualitative analysis. *BMC Rheumatology* 2018;2 (1) (no pagination).
19. Nevskaya T, **Baron M**, Baxter C, Ramey D, Pope J. Changes in skin scores predict internal organ involvement in early diffuse systemic sclerosis. *Journal of Rheumatology* 2018;45 (7):1061.
20. Qendro T, De La Torre M, Panopalis P, Hazel E, Colmegna I, **Hudson M**. Suboptimal immunization coverage among rheumatology patients in routine clinical care. *Journal of Rheumatology* 2018;45 (7):965.
21. Qendro T, De La Torre ML, Panopalis P, Hazel E, Colmegna I, **Hudson M**. Suboptimal immunization coverage among rheumatology patients in routine clinical care. *Arthritis and Rheumatology* 2018;70 (Supplement 9):1343.
22. Salituri J, **Hudson M**, Nathalie P, Berkson L, **Baron M**. Activation of mammalian target of rapamycin in renal tissue of patients with scleroderma renal crisis: A hypothesis-testing study. *Journal of Rheumatology* 2018;45 (7):1011.
23. Sinai L, Nevskaya T, Wang M, **Baron M**, Pope J. Long-term outcome of patients with systemic sclerosis: Predictors of organ damage using trajectory models in a large Canadian scleroderma inception cohort. *Journal of Rheumatology* 2018;45 (7):1061.
24. Turner K, Kwakkenbos L, Sanchez T, Carrier M, Mouthon L, **Hudson M**, Van Den Ende E, Schouffoer A, Welling J, Sauve M, Thombs B. The association of sociodemographic and disease

- variables with hand function in systemic sclerosis: A scleroderma patient-centered intervention (SPIN) cohort study. *Journal of Scleroderma and Related Disorders* 2018;3 (Supplement 1):114.
25. Wojcik S, Galatas C, Huynh T, Iacoviello L, Wang M, **Hudson M, Baron M**. Electrocardiographic findings in systemic sclerosis are very similar to those of healthy individuals: Data from the canadian scleroderma research group. *Journal of Scleroderma and Related Disorders* 2018;3 (Supplement 1):102-3.
 26. Zheng B, Nevskaya T, Pope J, Baxter C, Ramey D, **Baron M**. Improvement in skin score after 2 years in early diffuse cutaneous systemic sclerosis (dcSSc) patients is associated with improvement in multiple other domains of disease measurement. *Journal of Rheumatology* 2018;45 (7):1013.
 27. Zheng B, Wang M, **Baron M**. Immunosuppression in diffuse systemic sclerosis improves outcomes using a novel composite response index. *Arthritis and Rheumatology* 2018;70 (Supplement 9):2094-5.
 28. Zhu J, Gale C, Biber J, Nikpour M, **Baron M**, Frech TM. What do patient reported outcomes for routine monitoring of gastrointestinal tract symptoms in a systemic sclerosis center tell us about clinical features of potential small intestinal bacterial overgrowth? *Arthritis and Rheumatology* 2018;70 (Supplement 9):1933-4.
 29. Barsotti S, **Leclair V**, Notarnicola A, Elkhholm L, Dani L, Dastmalchi M, Lundberg E. Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. *Arthritis and Rheumatology* 2018;70 (Supplement 9);2540-1.

3. Grant reviews

Hudson, Dr. Marie

-CIORA grant review committee Chair (awards approximately \$700,000/year; third largest funding agency for arthritis research in Canada)

SECTION III - CONFIDENTIAL INFORMATION

1. Consulting activities:

Name of Faculty Member	Private Sector Consulting (# of days)	Public Sector Consulting (# days)	Other (# of days – please explain)	Total
Fallavollita, S.	Abbott		2 days	2
Fallavollita, S.	Janssen		2 days	2
Fallavollita, S.	BMS		1 day	1
Fallavollita, S.	Roche		1 day	1
Fallavollita, S.	UCB		1 day	1

Submitted by:

Murray Baron, MD

Chief, Division of Rheumatology, JGH